Cells from people who lived to 100, to help others reach 100.
We harness the biology of centenarians — nature's only proven longevity phenotype — and manufacture their MSC-derived exosomes at scale via proprietary microgravity technology.
Dowrey et al., Aging Cell 2025 · ARDD 2026 · BioPunk / Frontier Tower, SF
Why centenarians are the answer
Centenarians possess MSCs with superior DNA repair, enhanced proteostasis, and optimised metabolism — cells that have proven their resilience over 100+ years of biological stress. Their immune systems demonstrate compressed morbidity, avoiding the chronic inflammation that drives age-related disease in the rest of us.
The Dowrey et al. iPSC bank (Aging Cell, 2025) established the first longevity-specific stem cell repository from centenarian donors and their offspring. We ran proteomics across 3,977 proteins and applied ESM-2 transformer embeddings to identify 33 proteins consistently elevated in people who lived past 100.
Critically, 79% of these proteins are absent from the organ aging clocks identified across three major cohorts (Wang et al., Nature Aging 2025) — indicating an underexplored axis of longevity biology. These are our exosome cargo targets.
(higher in centenarians)
significance
A lead exosome-cargo candidate. Activates AMPK and suppresses mTOR, restoring metabolic and inflammatory balance — the first arm of the putative tumour-apoptosis mechanism.
How centenarian cargo converges on apoptosis
Our working model: centenarian MSC-derived exosomes deliver elevated cargo proteins into a tumour cell, where independent signalling arms — metabolic (ADIPOQ → AMPK/mTOR), redox (SOD3), growth-factor (IGFBP2 → PI3K–AKT), and lipid (PTGDS → PPARγ) — converge on mitochondrial priming and caspase-3/7 apoptosis, with growth arrest as a secondary outcome. Network analysis across all 3,977 proteins, using ESM-2 embeddings, maps these routes before any lead advances.
Mechanism model · ESM-2 validatedMSC expansion accounts for approximately 96% of batch time in co-production models — the single most impactful manufacturing cost lever. The Clinostat — part of a novel bioreactor system — is an Arduino-controlled, variable-speed unit that creates microgravity conditions to lift MSC yield and enrich exosome cargo quality at the same time.
Manufacturing advantage built in from day one
Cell expansion is the bottleneck in every MSC/exosome co-production pipeline. Most programmes don't own this layer. We do.
The Clinostat creates conditions to both increase MSC yield and — we hypothesise — enrich the secretome quality. First wet-lab experiments are running now at BioPunk / Frontier Tower, San Francisco, generating the first proprietary data on the microgravity–secretome relationship.
Centenarian MSC sourcing is in active negotiation with a leading academic centenarian-study biobank.
Three axes no competitor combines
Centenarian biology
Access to iPSC lines reprogrammed from centenarian donors (Dowrey et al., Aging Cell 2025) — cells that have proven their resilience over 100+ years, with superior DNA repair, enhanced proteostasis, and optimised metabolism.
Microgravity enhancement
Proprietary culture protocols on the Clinostat — part of a novel bioreactor system — our Arduino-controlled, variable-speed unit. MSC expansion accounts for ~96% of batch time; owning this layer is the primary manufacturing cost lever.
ESM-2 safety validation
Protein-protein interaction network analysis across 3,977 proteins using ESM-2 transformer embeddings. Mechanism-of-action elucidation and pre-clinical risk assessment before any lead advances.
A category forming now, with no approved products yet
Global exosome therapeutics + cosmeceuticals by 2030
Longevity-focused cosmeceuticals and therapeutics
Centenarian-derived MSC exosomes with ESM-2-validated safety
Cosmeceutical serum
First commercial product — a centenarian-derived exosome formulation for topical delivery. Bypasses the FDA therapeutic timeline while generating revenue, real-world safety data, and brand credibility ahead of the therapeutic programme.
Therapeutic indications
A formal IND-track programme targeting cancer and the diseases of aging — built on the safety profile and clinical data generated through the cosmeceutical route.
Peer-reviewed foundations, a track record of translation
ARDD 2026
Poster accepted at the Aging Research and Drug Discovery Meeting, Copenhagen, August. Presenting centenarian proteomics findings and organ aging clock analysis.
Dowrey et al., Aging Cell 2025
The first longevity-specific iPSC bank from centenarians and their offspring — the scientific foundation for our centenarian cell sourcing strategy.
IMANs in clinical trial
Our founder discovered IMANs (immature anti-tumour neutrophils) at Lift Biosciences. That work is now in active clinical trials, establishing a track record of bench-to-clinic translation.
Former Head of Research at Lift Biosciences, where he discovered IMANs — immature anti-tumour neutrophils now in clinical trials. Previously CEO of Virovax and founder of Elucida Health.
AI and computational engineering lead at TestNexus.AI. Hardware architect of the Clinostat, our proprietary microgravity MSC expansion system.
Advisory board forming · NASA GeneLab scientists · Academic regenerative-medicine partners
Follow the research
We publish findings as we generate them. Join the waitlist for updates on the centenarian biology platform, wet-lab results, and commercial progress.
Investor enquiries · founders@gravitate.bio